As of 2025-05-23, the Intrinsic Value of Neurocrine Biosciences Inc (NBIX) is 151.06 USD. This NBIX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 119.12 USD, the upside of Neurocrine Biosciences Inc is 26.80%.
The range of the Intrinsic Value is 108.14 - 275.66 USD
Based on its market price of 119.12 USD and our intrinsic valuation, Neurocrine Biosciences Inc (NBIX) is undervalued by 26.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 108.14 - 275.66 | 151.06 | 26.8% |
| DCF (Growth 10y) | 141.02 - 348.88 | 194.58 | 63.3% |
| DCF (EBITDA 5y) | 121.96 - 139.32 | 127.73 | 7.2% |
| DCF (EBITDA 10y) | 146.34 - 174.63 | 157.04 | 31.8% |
| Fair Value | 86.24 - 86.24 | 86.24 | -27.60% |
| P/E | 62.51 - 84.68 | 73.24 | -38.5% |
| EV/EBITDA | 93.50 - 113.11 | 101.79 | -14.5% |
| EPV | 47.49 - 56.62 | 52.06 | -56.3% |
| DDM - Stable | 23.60 - 58.27 | 40.93 | -65.6% |
| DDM - Multi | 34.93 - 69.00 | 46.59 | -60.9% |
| Market Cap (mil) | 11,785.73 |
| Beta | 0.65 |
| Outstanding shares (mil) | 98.94 |
| Enterprise Value (mil) | 10,709.63 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.28% |
| Cost of Debt | 4.25% |
| WACC | 7.18% |